An interventional study of Electronic Moxibustion and ibuprofen or celecoxib analgesics in Electronic Moxibustion, Low Back Pain and Muscle Hardness, sponsored by Nanfang Hospital, Southern Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Nanfang Hospital, Southern Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Low Back Pain with a site in China — 17 open to participants now, 19 under way, none of them phase 3. Low Back Pain · China.
Among the 49 studies in Low Back Pain with a site in China, this one is the 17th largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 12 of the 18 other live ones, and was the 47th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →17 of the 49 studies in Low Back Pain with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Universiti Sains Malaysia · Sites in China
Ages 20–55
Xijing Hospital · Sites in China
Ages 18–65
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 2
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 84 across the 42 interventional studies, 300 across the 7 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 49 have an industry lead sponsor. The 10 most frequent:
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.
Nanfang Hospital, Southern Medical University has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
3 of the studies in Low Back Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703671Beijing HospitalElectroacupuncture Treatment for Discogenic Low Back Pain | 2026-12-01 |
| NCT07892846Chinese PLA General HospitalThe Intervention Effect of Exercise on Lumbar Multifidus Muscle Injuries | 2027-05 |
| NCT07858188Nanfang Hospital, Southern Medical UniversityStudy on the Effect of Electronic Moxibustion on Non-Specific Low Back Pain in Young Adults | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Low Back Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an interventional clinical study. A total of 90 subjects aged 18 to 40 years are planned to be recruited. The subjects have low back pain that affects daily work and life, resulting in reduced exercise tolerance or aggravated pain after exercise, while retaining basic living ability and being capable of performing partial activities; their VAS scores range from 4 to 6. At baseline, the duration of subjects' low back pain and disability index will be recorded, along with muscle stiffness and electroencephalogram findings. Afterwards, electronic moxibustion treatment will be administered for 4 weeks. Subjects will be randomly divided into a treatment group and a control group with equal numbers of participants. The treatment group will use a Wenyang instrument with a rated frequency of 50 Hz, with the temperature set between 40℃ and 60℃ based on subjects' comfort level. Each treatment session lasts 30 to 60 minutes, 5 times per week for 4 weeks. The Wenyang instrument is used by subjects at home, with researchers providing remote guidance and supervision via voice or video. Subjects will check in and upload records after each use of electronic moxibustion, which will be documented by researchers. If subjects suffer from unbearable low back pain during the study, they may take oral ibuprofen or celecoxib for pain relief. The dosage and administration time will be recorded, and check-in and upload will be completed after each dose of analgesics for researchers' documentation. Subjects in the control group will take oral ibuprofen or celecoxib for pain relief as needed (i.e., when they feel pain). The dosage and administration time will be recorded with check-in and upload. After 4 weeks of intervention, the two groups will be compared in terms of the number of days of analgesic use or total consumed dosage, as well as changes in VAS scores, disability index, muscle stiffness and electroencephalogram findings.
This is an interventional clinical study. A total of 90 subjects aged 18 to 40 years are planned to be recruited. The subjects have low back pain that affects daily work and life, resulting in reduced exercise tolerance or aggravated pain after exercise, while retaining basic living ability and being capable of performing partial activities; their VAS scores range from 4 to 6. At baseline, the duration of subjects' low back pain and disability index will be recorded, along with muscle stiffness and electroencephalogram findings. Afterwards, electronic moxibustion treatment will be administered for 4 weeks. Subjects will be randomly divided into a treatment group and a control group with equal numbers of participants. The treatment group will use a Wenyang instrument with a rated frequency of 50 Hz, with the temperature set between 40℃ and 60℃ based on subjects' comfort level. Each treatment session lasts 30 to 60 minutes, 5 times per week for 4 weeks. The Wenyang instrument is used by subjects at home, with researchers providing remote guidance and supervision via voice or video. Subjects will check in and upload records after each use of electronic moxibustion, which will be documented by researchers. If subjects suffer from unbearable low back pain during the study, they may take oral ibuprofen or celecoxib for pain relief. The dosage and administration time will be recorded, and check-in and upload will be completed after each dose of analgesics for researchers' documentation. Subjects in the control group will take oral ibuprofen or celecoxib for pain relief as needed (i.e., when they feel pain). The dosage and administration time will be recorded with check-in and upload. After 4 weeks of intervention, the two groups will be compared in terms of the number of days of analgesic use or total consumed dosage, as well as changes in VAS scores, disability index, muscle stiffness and electroencephalogram findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group used a Yang-warming instrument with a rated frequency of 50 Hz. The temperature was set at 40-60 °C, adjusted mainly according to the subject's comfort level. Each treatment lasted 30-60 minutes, with 5 sessions per week for 4 consecutive weeks. Subjects used the Yang-warming instrument at home, and researchers provided remote guidance and supervision via voice or video calls. Subjects checked in and uploaded records after each session of electronic moxibustion, which were documented by researchers. If subjects experienced unbearable lumbago during the study, they could take oral ibuprofen or celecoxib for pain relief. The dosage and time of medication were recorded, and check-in records were uploaded after each painkiller administration for researchers' documentation.
Other: Electronic Moxibustion
In the control group, subjects took oral ibuprofen or celecoxib analgesics at an unspecified time (i.e., when the subjects felt pain). The dosage and time of medication were recorded and uploaded via check-in.
Drug: ibuprofen or celecoxib analgesics
The subjects were equally divided into the experimental group and the control group. The experimental group received electronic moxibustion 5 times a week for 4 weeks, used painkillers when experiencing subjective pain, and uploaded check-in records.
The control group took oral painkillers when experiencing subjective pain and uploaded check-in records.
Drug dosage
Total consumption of painkillers during the two groups of trials (within four weeks).
Time frame: Starting from the measurement baseline until the end of the 4-week intervention period, the difference in medication dosage used by the two groups during the intervention will be evaluated.
Plan to share: No — Individual-participant data will not be shared publicly due to participant privacy protection requirements, and the informed consent does not include provisions for open data sharing.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →